转移性黑色素瘤实施检查点抑制剂和靶向药物后长期生存者的医疗保健与社会经济成本
基于丹麦转移性黑色素瘤数据库和国家患者登记处,比较2007-2011年与2012-2016年实施检查点抑制剂和靶向治疗前后长期生存者的医疗成本、社会转移收入及生产力损失;2012-2016年长期生存者比例从15%升至32%,药品成本增加三倍以上,但首年总医疗成本显著降低,生产力提高。
要点
- 2012-2016年长期生存者比例32%(347/1089),2007-2011年为15%(70/464)。
- 首年总医疗成本2012-2016年显著低于2007-2011年(相对变化0.72)。
- 药品成本首年增加至3.39倍,第二年增加至2.59倍。
核心结论
- 实施靶向治疗和检查点抑制剂使长期生存者的药品成本增加三倍以上。
- 2012-2016年首年总医疗成本(不含药品)显著低于2007-2011年,第二年无显著差异。
- 治疗患者数量增加导致总医疗保健成本整体增加。
- 2012-2016年长期生存者的生产力提高。
研究设计与样本
- 基于丹麦转移性黑色素瘤数据库(DAMMED)和国家患者登记处的真实世界数据比较研究。
- 比较2007-2011年与2012-2016年(实施检查点抑制剂和靶向治疗后)注册的患者。
- 采用两步单模型广义线性回归(GLM)计算医疗成本、社会转移收入(STI)和生产力损失,药品成本单独计算。
主要发现
- 2007-2011年464例患者中70例(15%)为长期生存者,2012-2016年1089例中347例(32%)为长期生存者。
- 首年每患者年总医疗成本:2007-2011年€41.457 vs 2012-2016年€60.547,相对变化0.72(95%CI 0.56-0.94,p=0.015)。
- 第二年每患者年总医疗成本在2012-2016年与2007-2011年间无显著差异。
- 首年每患者年药品成本:2007-2011年€26.339 vs 2012-2016年€85.464,相对变化3.39(95%CI 2.61-4.41,p<0.001)。
- 第二年每患者年药品成本:2007-2011年€11.150 vs 2012-2016年€26.464,相对变化2.59(95%CI 1.98-3.40,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-life data on health care costs and loss of productivity after implementing new agents for metastatic melanoma are important to supplement model-based economic data. MATERIALS AND METHODS: All patients registered in the Danish Metastatic Melanoma Database (DAMMED) and the National Patient Registry in 2007-2011 were compared to 2012-2016 after the implementation of checkpoint inhibitors and targeted therapy. Health care costs, social transfer income (STI), and loss of productivity were calculated with a 2-step one model generalised linear regression (GLM) model. Medicine costs were calculated separately. RESULTS: In 2007-2011, 70 (15%) out of 464 patients were long-term survivors compared to 347 (32%) out of 1089 patients in 2012-2016. Total health care costs per patient year were significantly lower in the first treatment year (€41.457 versus €60.547, relative change (RC) 0.72, 95% confidence interval (CI) 0.56-0.94, p = 0.015) and without significant difference the second year in 2012-2016 compared to 2007-2011. Medicine costs per patient year increased the first (€85.464 versus €26.339, RC 3.39, 95% CI 2.61-4.41, p < 0.001) and the second (€26.464 versus €11.150, RC 2.59, 95% CI 1.98-3.40, p < 0.001) year in 2012-2016 compared to 2007-2011. Productivity increased for long-term survivors in 2012-2016 in contrast to 2007-2011. CONCLUSION: Implementation of targeted therapy and checkpoint-inhibitors has increased medicine costs more than three-fold for long-term survivors. Total health care costs excluding medicine costs were significantly lower for long-term survivors the first and without change the second treatment year in 2012-2016 compared to 2007-2011. However, the number of treated patients increased which leads to an increase in overall total health care costs. Importantly, productivity increased for long-term survivors in 2012-2016.
引用
- Soerensen AV, Kjellberg J, Ibsen R, et al. Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma. Eur J Cancer. 2023. PMID: 37672816. doi:10.1016/j.ejca.2023.113288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。